Not All Bruton's Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors

Authors

  • Giorgio Minotti, MD

Abstract

As the therapeutic landscape for B-cell malignancies continues to evolve, understanding the pharmacologic nuances of BTK inhibition has become increasingly important. In this interview, Rohit Khanna, publisher of Canadian Hematology Today, speaks with Giorgio Minotti, Professor of Pharmacology at the Università Campus Bio-Medico in Rome about the mechanistic differences between covalent and noncovalent BTK inhibitors, and the clinical implications for BTK inhibitor efficacy, resistance, and safety.

Author Biography

Giorgio Minotti, MD

Giorgio Minotti is Professor of Pharmacology and Clinical Pharmacology at the University Campus Bio-Medico of Rome, and Scientific Director of Fondazione Pisana per la Scienza in Pisa, Italy. He is primarily interested in basic and clinical research on new anticancer drugs, with a focus on pharmacodynamic and pharmacokinetic correlates of activity and toxicity, He has worked as a Fellow of the Italian Association for Cancer Research and Fulbright Scholar at Michigan State University, Michigan, USA, and as a Fulbright Visiting Professor at Case Western Reserve University, Ohio, USA. Prof. Minotti is Editor-in-Chief of Chemotherapy, co-founder and European Deputy Editor of Cardiooncology, Associate Editor for the Clinical Pharmacology section of the Journal of Pharmacology and Experimental Therapeutics. He served as expert pharmacologist for the Italian Ethics Committee on Advanced Therapies and Medicinal Products. He received grants from NATO Scientific Affairs, Italian Association for Cancer Research, Italian Ministry for Research and Italian Ministry for Public Health.

References

N/A

Downloads

Published

2026-05-20

How to Cite

1.
Not All Bruton’s Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors. Can Hematol Today [Internet]. 2026 May 20 [cited 2026 May 20];5(s02):2–7. Available from: https://canadianhematologytoday.com/article/view/5-s02-Minotti

Issue

Special Supplement, Spring 2026

Section

Articles

License

Copyright (c) 2026 Canadian Hematology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

1.
Not All Bruton’s Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors. Can Hematol Today [Internet]. 2026 May 20 [cited 2026 May 20];5(s02):2–7. Available from: https://canadianhematologytoday.com/article/view/5-s02-Minotti